Cargando…
The potential of glucagon-like peptide-1 receptor agonists in heart failure
Heart failure (HF) remains one of the cardiovascular diseases (CVDs) associated with a high unmet medical need due to high morbidity and mortality rates and lack of efficacious interventions. HF is closely related to cardiometabolic diseases such as diabetes, obesity and chronic kidney disease, and...
Autores principales: | Kreiner, Frederik Flindt, Hovingh, G. Kees Kornelis, von Scholten, Bernt Johan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9531309/ https://www.ncbi.nlm.nih.gov/pubmed/36203939 http://dx.doi.org/10.3389/fphys.2022.983961 |
Ejemplares similares
-
Glucagon‐like peptide‐1 receptor agonists to expand the healthy lifespan: Current and future potentials
por: Kreiner, Frederik Flindt, et al.
Publicado: (2023) -
The potential of GLP-1 receptor agonists in type 2 diabetes and
chronic kidney disease: from randomised trials to clinical
practice
por: von Scholten, Bernt Johan, et al.
Publicado: (2022) -
Glucagon-like peptide-1 receptor agonist use is associated with lower blood ferritin levels in people with type 2 diabetes and hemochromatosis: a nationwide register-based study
por: Bain, Stephen C, et al.
Publicado: (2023) -
Insulin at 100: still central in protein-based therapy for chronic disease
por: Kurtzhals, Peter, et al.
Publicado: (2021) -
Differential effects of glucagon-like peptide-1 receptor agonists on heart rate
por: Lorenz, Martin, et al.
Publicado: (2017)